DNM1L and ovarian serous adenocarcinoma: According to TCGA data the DNM1L gene is amplified in >50% serous ovarian cancer cases (5% high level amplification, 46% low level gain), while only 7% of cases show heterozygous loss (Appendix Fig. S8A).